Ladenburg Thalmann Financial Services’s Scinai Immunotherapeutics SCNI Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$23K	Hold	25	–	–	﹤0.01%	4075
2019 Q3	$14K	Hold	25	–	–	﹤0.01%	4237
2019 Q2	$14K	Hold	25	–	–	﹤0.01%	4272
2019 Q1	$14K	Hold	25	–	–	﹤0.01%	4213
2018 Q4	$12K	Hold	25	–	–	﹤0.01%	4189
2018 Q3	$14K	Hold	25	–	–	﹤0.01%	4113
2018 Q2	$14K	Hold	25	–	–	﹤0.01%	4060
2018 Q1	$14K	Hold	25	–	–	﹤0.01%	4060
2017 Q4	$13K	Hold	25	–	–	﹤0.01%	4050
2017 Q3	$18K	Buy	+25	New	+$20.5K	﹤0.01%	3747

Other funds holding SCNI

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

BHB

Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RWB

RMR Wealth Builders Montclair, New Jersey $1.61B AUM 27.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Ladenburg Thalmann Financial Services's SCNI Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Scinai Immunotherapeutics (SCNI) position steady in Q4 2019 at 25 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #4075.

Ladenburg Thalmann Financial Services first reported a position in SCNI in Q3 2017 and has held it in 10 quarters since. 11 funds tracked by Wall St. Rank hold SCNI as of Q4 2019.

Ladenburg Thalmann Financial Services held 25 shares of Scinai Immunotherapeutics worth $23K as of Q4 2019.
Ladenburg Thalmann Financial Services left its Scinai Immunotherapeutics share count unchanged in Q4 2019.
Scinai Immunotherapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4075 holding.
Ladenburg Thalmann Financial Services first reported a position in Scinai Immunotherapeutics in Q3 2017 and has held it in 10 quarters since.
11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.